Phathom Pharmaceuticals, Inc. (PHAT) vs ProKidney Corp. (PROK)
A side-by-side comparison of Phathom Pharmaceuticals, Inc. and ProKidney Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PHAT
Phathom Pharmaceuticals, Inc.
$6.78HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PROK
ProKidney Corp.
$1.60HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — PHAT vs PROK
growth of $100 · dividends reinvested · last 5yPHAT -80.2% (-27.7%/yr)PROK -84.4% (-31.0%/yr)PHAT compounded faster over this window
PHAT PROK
PHAT vs PROK: by the numbers
- •PHAT is the larger company ($549M vs $538M market cap).
- •Both run net losses; PHAT's is the smaller (-41.34% vs -10599.76% net margin).
Metrics side by side
Valuation
| Metric | PHAT | PROK |
|---|---|---|
| P/S ratio | 2.29 | 657.71 |
Profitability
| Metric | PHAT | PROK |
|---|---|---|
| Gross margin | 82.92% | 100.00% |
| Operating margin | -91.36% | -18477.83% |
| Net margin | -41.34% | -10599.76% |
| ROIC | -23.45% | -78.31% |
Growth (annualized)
| Metric | PHAT | PROK |
|---|---|---|
| Total return CAGR (5Y) | -26.93% | -30.65% |
Frequently asked
- How have PHAT and PROK total returns compared?
- Over the past 5 years, PHAT delivered -26.93% and PROK delivered -30.65% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.